PMID- 33342335
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1557-9891 (Electronic)
IS  - 1557-9883 (Print)
IS  - 1557-9883 (Linking)
VI  - 14
IP  - 6
DP  - 2020 Nov-Dec
TI  - Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to 
      Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction 
      Associated With Benign Prostatic Hyperplasia: A Meta-Analysis.
PG  - 1557988320980180
LID - 10.1177/1557988320980180 [doi]
LID - 1557988320980180
AB  - We report safety and efficacy of a combination therapy, comprising tamsulosin and 
      phosphodiesterase type 5 inhibitors (PDE5-Is), relative to monotherapy, to 
      ascertain its potential in treating lower urinary tract symptoms (LUTS) and 
      erectile dysfunction (ED) secondary to benign prostatic hyperplasia (BPH) after 3 
      months' treatment. We screened MEDLINE, EMBASE, and the Cochrane Controlled 
      Trials Register databases, for randomized controlled trials, and obtained eight 
      articles comprising 1144 participants. Results showed that the combination group 
      had superior outcomes with regard to International Prostate Symptom Score (IPSS) 
      and Qmax, compared to the other two groups. The combination group also had 
      superior efficacy with regard to International Index of Erectile Function (IIEF) 
      than the tamsulosin group, but not over the PDE5-Is group. Further, the 
      combination group showed better efficacy in IPSS voiding and quality of life 
      (QoL) compared to the PDE5-Is group. An analysis of safety outcomes revealed 
      extremely high adverse events (AEs) and pain in the combination group. However, 
      therapy discontinuation due to pain and AEs did not increase with increase in 
      AEs. Overall, our findings indicate that a combination of tamsulosin and PDE5-Is 
      is superior to individual tamsulosin and PDE5-Is monotherapy, with regard to 
      improving LUTS and ED secondary to BPH.
FAU - Sun, Kai
AU  - Sun K
AD  - Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao 
      University, Yantai, Shandong, China.
FAU - Sun, Fengze
AU  - Sun F
AD  - Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao 
      University, Yantai, Shandong, China.
FAU - Yao, Huibao
AU  - Yao H
AD  - Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao 
      University, Yantai, Shandong, China.
FAU - Zhang, Dongxu
AU  - Zhang D
AD  - Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao 
      University, Yantai, Shandong, China.
FAU - Wu, Gang
AU  - Wu G
AD  - Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao 
      University, Yantai, Shandong, China.
FAU - Wang, Tianqi
AU  - Wang T
AD  - Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao 
      University, Yantai, Shandong, China.
FAU - Wang, Jipeng
AU  - Wang J
AD  - Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao 
      University, Yantai, Shandong, China.
FAU - Wu, JiTao
AU  - Wu J
AUID- ORCID: 0000-0001-8866-8838
AD  - Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao 
      University, Yantai, Shandong, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Mens Health
JT  - American journal of men's health
JID - 101287723
RN  - 0 (Phosphodiesterase 5 Inhibitors)
RN  - 742SXX0ICT (Tadalafil)
RN  - G3P28OML5I (Tamsulosin)
SB  - IM
CIN - Am J Mens Health. 2021 Jan-Feb;15(1):1557988321997725. PMID: 33632007
MH  - Drug Therapy, Combination
MH  - *Erectile Dysfunction/drug therapy/etiology
MH  - Humans
MH  - *Lower Urinary Tract Symptoms/drug therapy/etiology
MH  - Male
MH  - Phosphodiesterase 5 Inhibitors/therapeutic use
MH  - *Prostatic Hyperplasia/complications/drug therapy
MH  - Quality of Life
MH  - Tadalafil/therapeutic use
MH  - Tamsulosin/therapeutic use
MH  - Treatment Outcome
PMC - PMC7756049
OTO - NOTNLM
OT  - general health and wellness
OT  - quality of life
OT  - sexual disorders
OT  - sexual dysfunction
OT  - sexual health
OT  - sexuality
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2020/12/22 06:00
MHDA- 2021/10/16 06:00
PMCR- 2020/12/21
CRDT- 2020/12/21 05:31
PHST- 2020/12/21 05:31 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2020/12/21 00:00 [pmc-release]
AID - 10.1177_1557988320980180 [pii]
AID - 10.1177/1557988320980180 [doi]
PST - ppublish
SO  - Am J Mens Health. 2020 Nov-Dec;14(6):1557988320980180. doi: 
      10.1177/1557988320980180.